Leidos Earns US Patent for Peptide-Based Treatment for Cancer, Infectious Diseases

This article was originally published here.

TYSONS CORNER, VA, January 8, 2018 — The Leidos (NYSE: LDOS) life sciences business unit has been awarded a patent for peptide-based PD-1 checkpoint inhibitors via the U.S. Patent and Trademark Office‘s accelerated application review process for cancer immunotherapy-related discoveries, ExecutiveBiz reported Friday.

The company said Thursday the Leidos Health Life Sciences team worked on methods that use peptides as an alternative therapeutic platform to the monoclonal antibody molecule class of therapeutics for cancer and infectious diseases in an effort to increase safety while limiting cost.

About Executive Mosaic: Founded in 2002, Executive Mosaic is a leadership organization and media company. Executive Mosaic offers highly coveted executive events, breaking business news on the Government Contracting industry, and robust and reliable content through seven influential websites and four consequential E-newswires. Headquarters are located in Tysons Corner, VA. www.executivemosaic.com

Contact:
Jason Scott
(703) 226-7003
jason.scott@executivemosaic.com

Keep reading about at GovCon Wire.